Immunomedics (www.immunomedics.com) is a clinical-stage biopharmaceutical company developing monoclonal antibody-based products for the targeted treatment of cancer.

Immunomedics’ corporate objective is to become a fully-integrated biopharmaceutical company and a leader in the field of Antibody-Drug Conjugates (ADC).

The US Food and Drug Administration (FDA) has granted fast-track designation for sacituzumab govitecan (IMMUNO-132).

Download to find out more.